Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis

Am J Kidney Dis. 2002 Jul;40(1):E2. doi: 10.1053/ajkd.2002.33933.

Abstract

Pamidronate is used frequently to treat malignancy-associated hypercalcemia and osteolytic lesions. This widely used bisphosphonate has been noted to cause nephrotoxicity in patients with multiple myeloma and metastatic breast cancer. We encountered a patient with Langerhans's histiocytosis who developed nephrotic syndrome and renal failure after pamidronate therapy. We describe the clinical and renal biopsy findings in this patient.

Publication types

  • Case Reports

MeSH terms

  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use
  • Diphosphonates / adverse effects*
  • Diphosphonates / therapeutic use*
  • Female
  • Histiocytosis, Langerhans-Cell / drug therapy*
  • Histiocytosis, Langerhans-Cell / pathology
  • Humans
  • Kidney Tubules / drug effects*
  • Kidney Tubules / pathology
  • Kidney Tubules / ultrastructure
  • Microscopy, Electron
  • Middle Aged
  • Nephrotic Syndrome / chemically induced
  • Nephrotic Syndrome / pathology
  • Pamidronate
  • Renal Insufficiency / chemically induced
  • Renal Insufficiency / pathology

Substances

  • Anti-Inflammatory Agents
  • Diphosphonates
  • Pamidronate